Regencell Bioscience Holdings (RGC) Notes Payables (2021 - 2025)

Regencell Bioscience Holdings' Notes Payables history runs 5 years deep, the most recent figure standing at $106.0 for Q4 2025.

• Quarterly Notes Payables changed N/A year-over-year to $106.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $106.0 (changed N/A YoY) and the FY2025 annual result came in at $2539.0, down 69.93% from the prior year.
• Notes Payables was $106.0 for Q4 2025 at Regencell Bioscience Holdings, down from $2539.0 in the prior quarter.
• Across five years, Notes Payables topped out at $82812.0 in Q2 2021 and bottomed at $106.0 in Q4 2025.
• A 5-year average of $20020.0 and a median of $9506.5 in 2023 frame the typical range for Notes Payables.
• Annual changes were most pronounced in 2022 — Notes Payables tumbled 81.1% — and 2024, when it slipped 20.12%.
• Regencell Bioscience Holdings' Notes Payables stood at $82812.0 in 2021, then tumbled by 81.1% to $15650.0 in 2022, then tumbled by 32.46% to $10570.0 in 2023, then declined by 20.12% to $8443.0 in 2024, then slumped by 98.74% to $106.0 in 2025.
• Business Quant data shows RGC's Notes Payables at $106.0 in Q4 2025, $2539.0 in Q2 2025, and $8443.0 in Q2 2024.